Juntendo Medical Journal 71(1), 2025 Reviews Juntendo Medical Journal 2025. 71(1), 43-50 Mechanisms of Itch in Atopic Dermatitis Yayoi KAMATA1), Mitsutoshi TOMINAGA1), Kenji TAKAMORI1, 2) 1)Juntendo Itch Research Center (JIRC), Institute for Environmental and Gender-Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan 2)Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan TEL: +81-47-353-3171 〔Received FAX: +81-47-353-3178 Sep. 20, 2024〕 〔Accepted E-mail: ykamata@juntendo.ac.jp Oct. 1, 2024〕 J-STAGE Advance published date: Jan. 30, 2025 Copyright © 2025 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ24-0036-R 43 Kamata Y, et al: Mechanisms of itch in atopic dermatitis Itch-scratch cycle The skin barrier primarily depends on the stratum corneum and tight junctions to protect the skin by preventing excess water loss and blocking allergen entry. Filaggrin (FLG) plays a crucial role in forming the stratum corneum by facilitating kerati­ nization, where living cells are transformed into hardened, dead cells called corneocytes4). FLG monomers are eventually degraded by proteases into free amino acids, known as natural moistur­ izing factors (NMF)3-6). The integrity of the skin barrier is essential for maintaining skin homeo­ stasis, but it can be compromised by genetic, envi­ ronmental, and other factors. FLG gene mutations, for example, have been identified as the cause of ichthyosis vulgaris, a condition often associated with AD7). Additional studies have confirmed this association and identified other loss-of-function mutations in the FLG gene that predispose individ­ uals to AD. These mutations are present in 7 to 10% of the white European population7, 8). Environ­ mental factors, such as scratching, exogenous prote­ ases of house dust mites, and Staphylococcus aureus, can also disrupt the skin barrier5). Other factors, such as decreased ceramide levels, further contribute to skin barrier dysfunction9). When the epidermal barrier is compromised, allergens can penetrate the skin more easily, interacting with local anti­ gen-presenting and immune effector cells5). This triggers the release of alarmins, such as thymic stromal lymphopoietin (TSLP) and interleukin (IL)-33, which in turn activate type 2 immune responses1). Activated T-helper (Th) 2 cells release IL-4 and IL-13, promoting IgE class switching in B cells and production of antigen-specific IgE1, 10). IL-4 and IL-13 also induce chemokine production in keratinocytes, which accelerates the infiltration of inflammatory cells into the skin11). Pruritus is an unpleasant sensation that serves as a self-protective mechanism, helping the body avoid harm from external irritants12, 13). In AD, pruritus is characterized by itch hypersensitivity, including alloknesis and hyperkinesis12, 13). Alloknesis refers to innocuous tactile stimuli, such as light touches from clothing, that evoke itching, while hyperkinesis refers to an exaggerated itch response to normal itchy stimuli. Although histamine is a well-known itch-inducing substance, antihistamines 44 (histamine H1-receptor blockers) are not fully effec­ tive in treating itch in AD14). This intractable itch is a clinical challenge that significantly reduces patients’ QOL. As shown in Figure 1, the dysfunctional barrier in AD leads to enhanced antigen penetration, exacer­ bating allergic reactions. Scratching further damages the skin barrier, worsens dryness, and increases the release of pro-inflammatory mediator, perpetu­ ating the itch-scratch cycle. Breaking this cycle with appropriate treatments is essential to manage itch effectively. Cutaneous barrier disruption and itch sensitivity In human skin, primary sensory afferents can be categorized by their degree of myelination, conduc­ tion velocity, axonal diameter, and nerve ending type15). Itch is primarily conducted by slow-con­ ducting, unmyelinated C fibers. Endogenous pruri­ togenic factors produced by epidermal keratino­ cytes and immune cells, such as mast cells and T cells, act on and excite sensory nerve fibers through their corresponding receptors and channels (Table 1). When sensory nerves are excited, they release itch transmitters like natriuretic peptide B, gastrinreleasing peptide, glutamate, and neurokinin B into the dorsal horn of the spinal cord. These neurotrans­ mitters stimulate neurons in the spinal dorsal horn, which then transmit itch signals to the brain via the spinal cord-thalamic tract or the spinal cordparabrachial nucleus tract16, 17). In healthy skin, most cutaneous nerve fibers termi­ Figure 1 The itch-scratch cycle In atopic dermatitis, a dysfunctional skin barrier allows increased antigen penetration, leading to aggravated allergic reactions. The loss of moisture and pathogen infiltration worsen dryness and inflammation, inducing an urge to scratch. Scratching further damages the skin barrier, increases dryness, and enhances the release of pro-inflammatory mediators, perpetuating a vicious itch-scratch cycle. Juntendo Medical Journal 71(1), 2025 Table 1 Category Itch mediators and receptors Itch mediators Receptor Amines Histamine Serotonin (5-HT) H1R, H4R, TRPV1 5-HT2A, 5-HT7, TRPV4 Proteases SLIGRL Tryptase Mucunain Cathepsin S Protease-activated receptor (PAR) -2, MrgprC11 PAR-2 PAR-2, PAR-4 PAR-2, PAR-4, MrgprC11 Neuropeptides Substance P Endothelin (ET)-1 NK1 receptor, MrgprA1 ETA receptor Lipids Platelet-activating factor (PAF) Lysophosphatidic acid (LPA) Leukotriene B4 (LTB4) PAF receptor LPA5, TRPA1 BLT1 receptor Cytokines IL-31 TSLP CXCL10 (IP-10) IL-31 RA, OSMR, TRPV1, TRPA1 TSLP receptor, TRPA1 CXCR3 Mrgpr agonist Chloroquine BAM8-22 β-alanine MrgprX1(human), MrgprA3(mouse), TRPA1 MrgprX1(human), MrgprC11(mouse), TRPA1 MrgprD Others Bile acid Oxidative stress TGR5, TRPA1 TRPA1 Figure 2 Regulation of axonal guidance molecule expression in skin In healthy skin, the levels of nerve repulsion factor (NRF), such as semaphorin 3A (Sema3A) are more dominant than nerve elongation factors (NEF), like nerve growth factor (NGF). This balance prevents nerve fibers from easily penetrating the epidermis. In contrast, in the lesional skin of atopic dermatitis (AD), NEF are more dominant than NRF, allowing nerve fibers to penetrate the epidermis. nate at the dermoepidermal junction (Figure 2)18). However, in barrier-disrupted skin, such as the lesional skin of AD or dry skin, an increased density of intraepidermal nerves has been observed, which contributes to itch sensitization. This hyperinner­ vation is partly responsible for increased itch sensi­ tivity. Since this type of pruritus does not involve histamine, H1-antihistamines are ineffective for 45 Kamata Y, et al: Mechanisms of itch in atopic dermatitis treating it. Additionally, intraepidermal nerve fiber terminals are usually trimmed at the tight junc­ tions of the stratum granulosum (SG) 2 layer19). In AD model mice, however, this trimming process is disrupted, leading to nerve fibers penetrating through and protruding into the outer skin layers, resulting in abnormal sensory nerve activation. Primary sensory nerves in the skin are responsible for transmitting itch signals. Recent single-cell RNA sequencing has classified the sensory neuron system into five neurofilament clusters, two clusters of peptidergic nociceptors, one tyrosine hydroxylase containing cluster, and three clusters of non-pepti­ dergic (NP) nociceptors20). Neurons in the NP1, NP2, and NP3 clusters express receptor genes for itch mediators20, 21). NP1 neurons strongly express Masrelated G protein coupled receptor (Mrgpr) D, while NP2 neurons express MrgprA3, MrgprC11, and the histamine H1 receptor. NP3 neurons express the IL-31 receptor, serotonin receptors, histamine H1 receptor, and leukotriene C4 receptors. All three clusters, NP1, NP2, and NP3, commonly express IL-4 and IL-13 receptors20, 21). However, it remains unclear which subsets of neurons are increased in AD lesions. Periostin, an extracellular matrix and matricel­ lular protein, is emerging as a significant player in itch sensation22-24). In human inflamed skin, such as in AD, periostin is deposited throughout the dermis. It acts on keratinocytes by activating NF-κB, leading to the production of pro-inflammatory cytokines, including TSLP25). Periostin also binds to αvβ3 integrin and directly stimulates nerve fibers, resulting in itch sensation26). Neuroimmune communication In the non-lesional skin of AD, keratinocytes secrete cytokines known as alarmins due to the disrupted skin barrier. These cytokines activate type 2 innate lymphoid cells, which in turn induce type 2 inflammation through IL-5 and IL-13. Th2 cells secrete IL-4, IL-13 and IL-31, playing an important role in the pathogenesis of AD10). In particular, IL-31 directly induces pruritus and increases in the lesional skin and serum of AD patients27-29). NP3 neurons express IL-31R, suggesting a significant contribution to itch20, 21). IL-31 is primarily produced by Th2 cells, mast cells, and macro­ phages30). Nemolizumab, a humanized IL-31RA 46 monoclonal antibody marketed as Mitchga, was approved in Japan in March 202231). In IL-31 trans­ genic mice, the number of PGP9.5+ nerve fibers and the thickness of epidermis increased in AD-like lesions32). IL-31RA is expressed on small-diameter neurons, and IL-31 selectively promotes nerve fiber extension in these neurons32, 33). Collectively, IL-31 is not only a mediator of itch but also induces neurite elongation. Some cytokines act as modulators rather than direct itch mediators, enhancing or attenuating itch. For instance, cytokines such as IL-4, IL-13, IL-33, and oncostatin M enhance itch34-37). IL-4, released from Th2 cells, binds to IL-4 receptors and is thought to induce itch and inflammation via the JAK-STAT pathway, contributing to the patho­ genesis of AD38). Although IL-4 does not directly induce itch, it enhances histamine-induced itch34). Intradermal co-injection of a low dose of histamine with IL-4 significantly increased scratching behavior in mice compared to histamine alone34). In dry or non-lesional skin of AD, IL-33 is secreted by kera­ tinocytes in barrier-disrupted skin, inducing itch sensitization16). In the lesional skin of AD, Th2 cyto­ kines (IL-4 and IL-13) play a key role in itch sensi­ tization16, 36). Currently, several biologics targeting cytokine signaling, including dupilumab, nemoli­ zumab, tralokinumab, and lebrikizumab are approved for use in Japan39). Regulatory mechanisms of intraepidermal nerve fibers In the lesional skin of AD, numerous nerve fibers penetrate the epidermis. Nerve elongation factors (NEF), such as nerve growth factor (NGF), promote neurite outgrowth, while nerve repulsion factors (NRF), like semaphorin 3A (Sema3A), inhibit it. In normal skin, NRF levels are more dominant than NEF, maintaining a balance that limits nerve fiber penetration into the epidermis. However, in the lesional skin of AD, NEF levels become dominant over NRF, allowing nerve fibers to more easily penetrate the epidermis. Both Sema3A and NGF are expressed in normal skin, but in AD lesions, Sema3A expression decreases while NGF expres­ sion increases40). These findings suggest that epidermal nerve density is regulated by a delicate balance between NEF and NRF16) (Figure 2). Previ­ ously, we developed an ointment containing recom­ Juntendo Medical Journal 71(1), 2025 binant Sema3A protein, which was applied to the lesional skin of AD model NC/Nga mice41). Sema3A ointment significantly inhibited epidermal hyperin­ nervation and reduced scratching behavior. It also improved barrier function and dermatitis in the AD model mice compared to controls41). However, there are challenges with clinical application. Proteinbased drugs tend to be unstable and have high production costs. Thus, we proposed that activa­ tors of endogenous Sema3A expression might offer a promising treatment for intractable itch in AD. Regulatory mechanisms of Sema3A in normal human epidermal keratinocytes Calcium is a major regulator of keratinocyte differentiation both in vivo and in vitro42, 43). It forms a gradient within the epidermis, with the highest concentration in the granular layer43). However, the acute disruption of the epidermal permeability barrier causes a loss of this calcium gradient43). Normal human epidermal keratinocytes (NHEK) undergo differentiation in the presence of high calcium levels (Figure 3). Sema3A mRNA levels were transiently increased in high calcium-stimu­ lated NHEK, but markedly decreased in terminally differentiated NHEK. Using in situ hybridization, Sema3A mRNA was primarily detected in keratin 14-positive keratinocytes in the stratum basale and lower stratum spinosum. Furthermore, we cons­ tructed a human Sema3A promoter assay system and analyzed Sema3A promoter activity in NHEK. Site-directed mutagenesis of the activator protein (AP)-1 binding site significantly reduced Sema3A promoter activity compared to the intact plasmid. AP-1 is a basic-leucine zipper transcription factor44) that forms multiple dimer pairs, such as Jun and Fos. AP-1 complexes are key regulators of kerati­ nocyte survival and differentiation, and they are important downstream targets of mitogen acti­ vated protein kinase (MAPK) signaling44-46). After Figure 3 Cell morphology of normal human epidermal keratinocytes (NHEK) during calcium-induced differentiation Phase-contrast images show NHEK cultured in medium containing 0.1 mM or 1.4 mM calcium. Microscopic images were taken at each time point after medium replacement. Scale bar: 100 μm. 47 Kamata Y, et al: Mechanisms of itch in atopic dermatitis stimulation with high calcium, JunB and Fra-2 were found to directly interact with the transcription factor-binding site in the proximal promoter region of Sema3A, as confirmed by chromatin immunopre­ cipitate assays. Sema3A expression increased when JunB and Fra-2 were co-expressed in the pres­ ence of 0.1 or 1.4 mM calcium, whereas overexpres­ sion of JunB or Fra-2 alone had no effect on Sema3A expression. Additionally, other combinations of Jun and Fos increased Sema3A mRNA expression. The MAPK-MEK/ERK1/2 pathway is involved in the differentiation of keratinocytes both in vivo and in vitro. The calcium-mediated transient up-regulation of Sema3A expression was significantly suppressed by the MEK1/2 inhibitor (PD98059) and the AP-1 inhibitor (T-5224). Taken together, we found that calcium-mediated transient upregulation of Sema3A in NHEK is dependent on the MEK/ERK and AP-1 signaling pathways47). In healthy skin, Sema3A is produced during the early stages of keratinocyte differentiation and may subsequently move into the upper epidermis. Why Sema3A expression decreases in AD lesions To investigate why Sema3A expression decreases in AD lesions, we conducted several analyses. Disruption of the epidermal barrier leads to the loss of the calcium gradient43), which may downreg­ ulate Sema3A expression in the epidermis. We hypothesized that inflammation and skin barrier defects are the primary causes of decreased Sema3A expression in AD. In a murine model, IL-4 has been reported to reduce Sema3A expression in the skin48). However, in NHEK, Th2 cytokines, such as IL-4 and IL-13, actually increased Sema3A mRNA expres­ sion. We also tested Sema3A gene expression in cytokine-stimulated reconstructed human epidermis (RHE) models, where IL-4 and IL-13 similarly increased Sema3A expression consistent with the results from monolayer cultures (unpublished data). Next, we performed a barrier disruption experi­ ment using detergent on the RHE model. Applying 0.2% Triton X-100 to the stratum corneum disrupted the epidermal barrier, causing transepidermal water loss to increase for 2 to 6 h before gradually decreasing over time (unpublished data). This suggested that barrier function deteriorated tempo­ rarily before recovery. Sema3A expression was transiently suppressed immediately after barrier 48 disruption, but markedly increased after 24 and 48 h. In contrast, NGF expression showed an initial increase initially, but decreased after 24 and 48 h. These changes may reflect compensatory responses to the recovery of barrier function. Similarly, in an acetone-treated dry skin mouse model, barrier disruption increased nerve fiber density in the epidermis49). Collectively, these findings suggest that in humans, cytokines alone may not directly downregulate Sema3A in AD lesions. Instead, barrier disruption likely plays a key role in Sema3A down­ regulation in AD. Development of Sema3A expression inducers Drug repositioning, a strategy for discovering new uses for approved or investigational drugs, has led to identifying Sema3A expression inducers. For example, thalidomide, initially developed for morning sickness, is now used to treat multiple myeloma50). Through drug repositioning, we screened the Prest­ wick Chemical Library aiming for Sema3A expres­ sion inducers. Among the 16 identified compounds, we focused on the antiparasitic drug parbendazole, which significantly induced Sema3A expression and secretion of NHEK (Unpublished data). Similar effects were observed with related antiparasitic drugs, fenbendazole and albendazole. These drugs also significantly suppressed NGF mRNA expres­ sion in NHEK. Other compounds that induce Sema3A expres­ sion include the antimicrobial peptide LL-37, a member of the cathelicidin family51), which we found to promote Sema3A expression52). Addition­ ally, extracts from Scutellaria baicalensis root, used in traditional herbal medicines, have been shown to promote Sema3A expression, with baicalin and baicalein identified as the active compounds53). Conclusions In AD lesions, many nerve fibers penetrate the epidermis. However, some studies suggest that while nerve fibers penetrate normal skin, their density decreases in AD lesions54, 55). We hypothe­ size that changes in epidermal nerve fiber density may depend on the disease state of AD. Since IL-4 and IL-13 did not decrease Sema3A expression, it is believed that axon guidance molecule regulation involves not only cytokines but also complex mech­ anisms, including barrier destruction. Sema3A is a Juntendo Medical Journal 71(1), 2025 key molecule in preventing itch sensitivity in AD lesions. In the future, we aim to establish methods to regulate Sema3A expression in skin, and clinical applications. Acknowledgments Not applicable. Funding This work was partly supported by JSPS KAKENHI (22K08412, 19K08756, 16K19739), Lydia O’leary Memorial Pias Dermatological Foundation (2020), Mandom International Research Grant (2022) and Hoyu Research Foundation (2024). Author contributions YK was a major contributor in writing the manu­ script. MT and KT contributed to reviewing and editing the manuscript. Conflicts of interest statement The authors declare that there are no conflicts of interest. References 1) Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD: Atopic dermatitis. Nat Rev Dis Primers, 2018; 4: 1. 2) Fishbein AB, Silverberg JI, Wilson EJ, Ong PY: Update on atopic dermatitis: Diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract, 2020; 8: 91-101. 3) Kabashima K: New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci, 2013; 70: 3-11. 4) Brown SJ, McLean WH: One remarkable molecule: filaggrin. J Invest Dermatol, 2012; 132: 751-762. 5) Cork MJ, Danby SG, Vasilopoulos Y, et al: Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol, 2009; 129: 1892-1908. 6) Kamata Y, Taniguchi A, Yamamoto M, et al: Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. J Biol Chem, 2009; 284: 12829-12836. 7) McGrath JA, Uitto J: The filaggrin story: novel insights into skin-barrier function and disease. Trends Mol Med, 2008; 14: 20-27. 8) McAleer MA, Irvine AD: The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol, 2013; 131: 280-291. 9) Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A: Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol, 1991; 96: 523-526. 10) Langan SM, Irvine AD, Weidinger S: Atopic dermatitis. Lancet, 2020; 396: 345-360. 11) Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K: The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. Immunol Rev, 2017; 278: 246-262. 12) Akiyama T, Carstens E: Neural processing of itch. Neuroscience, 2013; 250: 697-714. 13) Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M: The neurobiology of itch. Nat Rev Neurosci, 2006; 7: 535-547. 14) Klein PA, Clark RA: An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol, 1999; 135: 1522-1525. 15) Lowy DB, Makker PGS, Moalem-Taylor G: Cutaneous neuroimmune interactions in peripheral neuropathic pain states. Front Immunol, 2021; 12: 660203. 16) Tominaga M, Takamori K: Peripheral itch sensitization in atopic dermatitis. Allergol Int, 2022; 71: 265-277. 17) Yosipovitch G, Berger T, Fassett MS: Neuroimmune interactions in chronic itch of atopic dermatitis. J Eur Acad Dermatol Venereol, 2020; 34: 239-250. 18) Tominaga M, Takamori K: Itch and nerve fibers with special reference to atopic dermatitis: therapeutic impli­ cations. J Dermatol, 2014; 41: 205-212. 19) Takahashi S, Ishida A, Kubo A, et al: Homeostatic pruning and activity of epidermal nerves are dysregu­ lated in barrier-impaired skin during chronic itch development. Sci Rep, 2019; 9: 8625. 20) Usoskin D, Furlan A, Islam S, et al: Unbiased classifica­ tion of sensory neuron types by large-scale single-cell RNA sequencing. Nat Neurosci, 2015; 18: 145-153. 21) Toyama S, Tominaga M, Takamori K: Connections between immune-derived mediators and sensory nerves for itch sensation. Int J Mol Sci, 2021; 22: 12365. 22) Izuhara K, Arima K, Ohta S, Suzuki S, Inamitsu M, Yamamoto K: Periostin in allergic inflammation. Allergol Int, 2014; 63: 143-151. 23) Izuhara K, Nunomura S, Nanri Y, et al: Periostin in inflammation and allergy. Cell Mol Life Sci, 2017; 74: 4293-4303. 24) Hashimoto T, Mishra SK, Olivry T, Yosipovitch G: Peri­ ostin, an emerging player in itch sensation. J Invest Dermatol, 2021; 141: 2338-2343. 25) Shiraishi H, Masuoka M, Ohta S, et al: Periostin contrib­ utes to the pathogenesis of atopic dermatitis by inducing TSLP production from keratinocytes. Allergol Int, 2012; 61: 563-572. 26) Mishra SK, Wheeler JJ, Pitake S, et al: Periostin activa­ tion of integrin receptors on sensory neurons induces allergic itch. Cell Rep, 2020; 31: 107472. 27) Sonkoly E, Muller A, Lauerma AI, et al: IL-31: a new link between T cells and pruritus in atopic skin inflam­ mation. J Allergy Clin Immunol, 2006; 117: 411-417. 28) Takaoka A, Arai I, Sugimoto M, et al: Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol, 2006; 15: 161-167. 29) Raap U, Wichmann K, Bruder M, et al: Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol, 2008; 122: 421-423. 30) Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B: Signaling by IL-31 and functional consequences. Eur J Cell Biol, 2012; 91: 552-566. 31) Ruzicka T, Hanifin JM, Furue M, et al: Anti-inter­ leukin-31 Receptor A antibody for atopic dermatitis. N Engl J Med, 2017; 376: 826-835. 32) Feld M, Garcia R, Buddenkotte J, et al: The pruritusand TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol, 2016; 138: 49 Kamata Y, et al: Mechanisms of itch in atopic dermatitis 500-508. e24. 33) Kido-Nakahara M, Wang B, Ohno F, et al: Inhibition of mite-induced dermatitis, pruritus, and nerve sprouting in mice by the endothelin receptor antagonist bosentan. Allergy, 2021; 76: 291-301. 34) Oetjen LK, Mack MR, Feng J, et al: sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell, 2017; 171: 217-228. e13. 35) Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F: Mechanistic insights into the antipru­ ritic effects of lebrikizumab, an anti-IL-13 mAb. J Allergy Clin Immunol, 2022; 150: 690-700. 36) Trier AM, Mack MR, Fredman A, et al: IL-33 signaling in sensory neurons promotes dry skin itch. J Allergy Clin Immunol, 2022; 149: 1473-1480. e6. 37) Tseng PY, Hoon MA: Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med, 2021; 13: eabe3037. 38) Beck LA, Cork MJ, Amagai M, et al: Type 2 inflamma­ tion contributes to skin barrier dysfunction in atopic dermatitis. JID Innov, 2022; 2: 100131. 39) Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R: Updated review on treatment of atopic dermatitis. J Investig Allergol Clin Immunol, 2023; 33: 158-167. 40) Tominaga M, Tengara S, Kamo A, Ogawa H, Takamori K: Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci, 2009; 55: 40-46. 41) Negi O, Tominaga M, Tengara S, et al: Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis. J Dermatol Sci, 2012; 66: 37-43. 42) Bikle DD, Xie Z, Tu CL: Calcium regulation of kerati­ nocyte differentiation. Expert Rev Endocrinol Metab, 2012; 7: 461-472. 43) Elias PM, Ahn SK, Denda M, et al: Modulations in epidermal calcium regulate the expression of differen­ tiation-specific markers. J Invest Dermatol, 2002; 119: 1128-1136. 44) Shaulian E, Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol, 2002; 4: E131-E136. 50 45) Angel P, Szabowski A, Schorpp-Kistner M: Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene, 2001; 20: 2413-2423. 46) Mehic D, Bakiri L, Ghannadan M, Wagner EF, Tschachler E: Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol, 2005; 124: 212-220. 47) Kamata Y, Tominaga M, Umehara Y, et al: Calciuminducible MAPK/AP-1 signaling drives semaphorin 3A expression in normal human epidermal keratino­ cytes. J Invest Dermatol, 2020; 140: 1346-1354. e5. 48) Sakai T, Takahashi D, Nikaido K, et al: Co-stimulation with interleukin-4 and tumor necrosis factor-alpha increases epidermal innervation accompanied by suppression of semaphorin 3A. J Dermatol Sci, 2014; 76: 69-71. 49) Moniaga CS, Tominaga M, Takamori K: Mechanisms and management of itch in dry skin. Acta Derm Vene­ reol, 2020; 100: adv00024. 50) Jourdan JP, Bureau R, Rochais C, Dallemagne P: Drug repositioning: a brief overview. J Pharm Pharmacol, 2020; 72: 1145-1151. 51) Lehrer RI, Ganz T: Cathelicidins: a family of endoge­ nous antimicrobial peptides. Curr Opin Hematol, 2002; 9: 18-22. 52) Umehara Y, Kamata Y, Tominaga M, Niyonsaba F, Ogawa H, Takamori K: Cathelicidin LL-37 induces semaphorin 3A expression in human epidermal kerat­ inocytes: Implications for possible application to pruritus. J Invest Dermatol, 2015; 135: 2887-2890. 53) Yoshioka Y, Kamata Y, Tominaga M, et al: Extract of Scutellaria baicalensis induces semaphorin 3A produc­ tion in human epidermal keratinocytes. PLoS One, 2021; 16: e0250663. 54) Tsutsumi M, Kitahata H, Fukuda M, et al: Numerical and comparative three-dimensional structural anal­ ysis of peripheral nerve fibres in epidermis of patients with atopic dermatitis. Br J Dermatol, 2016; 174: 191-194. 55) Tan Y, Ng WJ, Lee SZX, et al: 3-Dimensional optical clearing and imaging of pruritic atopic dermatitis and psoriasis skin reveals downregulation of epidermal innervation. J Invest Dermatol, 2019; 139: 1201-1204.